NRXS Overview

Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.

Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neuraxis Inc revenue for the last quarter amounts to 968.13K USD, increased 27.19

Neuraxis Inc. EPS for the last quarter amounts to -0.18 USD, decreased -21.74

Neuraxis Inc (NRXS) has 24 emplpoyees as of May 04 2026.

Today NRXS has the market capitalization of 92.96M USD.